clinical trial · NCT06919666
NT219 Combined With Standard of Care Biologic Therapy in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
University of Colorado, Denver·phase2·active not recruiting·n = 29
Head and Neck CancerHead and Neck Squamous Cell CarcinomaNT219
brief summary
Fixed dose NT219 weekly plus pembrolizumab every 3 weeks or cetuximab weekly to be continued until progression, unacceptable toxicity, or investigator or participant decision.
started
Jun 12, 2025
primary completion
Feb 1, 2030
completion
Feb 1, 2031
last updated
Apr 6, 2026
official title
Phase Ib/II Study of NT219 in Combination With Pembrolizumab or Cetuximab in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol